Big pharma toll-road customer — Keytruda is the dominant PD-1 franchise ($29B+). Massive R&D engine that feeds the entire Measure→Manufacture→Package & Deliver pipeline. WINREVAIR (sotatercept) for PAH is the key pipeline catalyst.
Conviction●●●○○3 of 5
Research target—Snapshot target
Thesis statusACTIVE_RESEARCHLast reviewed Not reviewed
Market cap$319.99BSnapshot value
WINREVAIR (sotatercept) PAH launch ramp, Capvaxive pneumococcal vaccine launch, Keytruda label expansions (earlier-stage cancers), Gardasil China recovery
1. Keytruda LOE (2028) — inadequate pipeline replacement. 2. WINREVAIR fails to ramp (PAH market smaller than modeled). 3. Gardasil China structural decline. 4. IRA drug price negotiation impact deeper than expected. 5. Biosimilar Keytruda faster-than-expected uptake.
Split: value investors like the forward P/E; growth investors hate the LOE overhang. Institutional-heavy.
Snapshot · Not reviewedNo positioning snapshot available.
Snapshot · Not reviewed